TrialBritish journal of haematology2025

Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension.

Nichola Cooper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.